Skip to main content

Table 3 Colony formation efficiencies and number of established lines

From: Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector

Healthy donor and patients (hiPSC line) Colony formation efficiencies (No. of colonies/No. of seeded cells) No. of colonies per 1 mL blood No. of lines established Recovery success rate from frozen stock (No. of lines checked)
Healthy (TkPP2) 5.58% (781/14,000) 10 100% (2)
SLE (TkSLE3) 2.61% (339/13,000) 38.5 12 100% (6)
SLE (TkSLE4) 0.08% (12/16,000) 0.65 4 100% (4)
SLE (TkSLE5) 3.26% (1283/39,375) 171.1 12 100% (6)
PM (TkSPD3) 1.67% (130/7750) 17.4 12 100% (5)
PM (TkSPD4) 3.17% (246/7750) 59.1 14 100% (3)
PM (TkSPD5) 0.10% (16/14,000) 1.8 12 100% (6)
X-CGD (TkSCG3) 0.29% (23/7750) 1.7 12 100% (6)
X-CGD (TkSCG4) 0.26% (23/9000) 2.7 12 100% (6)
PID (TkSPR1) 2.43% (438/18,000) 83.2 12 100% (5)
PID (TkSPR2) 2.50% (294/11,750) 38.1 12 100% (6)
JIA (TkSCR1) 1.59% (530/33,375) 126.7 11 100% (6)
CMS (TkS42–1) 0.34% (17/5000) 1.2 14 100% (6)
MD (TkSmD1) 1.09% (85/7800) 4.6 26 100% (7)
MD (TkSmD3) 1.09% (215/19,763) 45.9 36 100% (13)
KCS2 (TkSKCII2) 0.15% (43/27,750) 8.9 12 100% (2)
  1. The colony formation efficiency of each seeded cell line and the estimated number of colonies per 1 mL of peripheral blood are shown. The ratios of the total number of emerged primary colonies/the total number of seeded cells are indicated in parentheses. The number of human induced pluripotent stem cell (hiPSC) lines established from each sample is also shown. The right-hand column shows the success rate of recovering lines from frozen stock, meaning that there were no failures in the freeze–thaw process for all the established stocks tested
  2. SLE Systemic lupus erythematosus, PM Polymyositis, X-CGD X-linked chronic granulomatous disease, PID Primary immunodeficiency, JIA Juvenile idiopathic arthritis, CMS Congenital malformation syndrome, MD Mitochondrial diabetes, KCS2 Kenny-Caffey syndrome type 2